Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5

References

• Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. Revised 4th Edition. Lyon: International Agency for Research on Cancer (IARC); 2016.
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Sonoda Y, Yokoo H, Tanaka S, Kinoshita M, Nakada M, Nishihara H. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain Tumor Pathol. 2019;36(2):56–62. doi:10.1007/s10014-019-00337-y
   PubMed Web of Science ®Google Scholar
• Onizuka H, Masui K, Komori T. Diffuse gliomas to date and beyond 2016 WHO classification of tumours of the central nervous system. Int J Clin Oncol. 2020;25(6):997–1003. doi:10.1007/s10147-020-01695-w
   PubMed Web of Science ®Google Scholar
• Komori T. The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community. Neuro Oncol. 2019;21(12):1485–1486. doi:10.1093/neuonc/noz186
   PubMed Web of Science ®Google Scholar
• Kondo T. Molecular mechanisms involved in gliomagenesis. Brain Tumor Pathol. 2017;34(1):1–7. doi:10.1007/s10014-017-0278-8
   PubMed Web of Science ®Google Scholar
• Louis DN, Aldape K, Brat DJ, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017;27(6):851–852. doi:10.1111/bpa.12457
   PubMed Web of Science ®Google Scholar
• Louis DN, Aldape K, Brat DJ, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 2017;133(1):1–3. doi:10.1007/s00401-016-1646-x
   PubMed Web of Science ®Google Scholar
• Yeaney GA, Brat DJ. What every neuropathologist needs to know: update on cIMPACT-NOW. J Neuropathol Exp Neurol. 2019;78(4):294–296. doi:10.1093/jnen/nlz012
   PubMed Web of Science ®Google Scholar
• Kristensen BW, Priesterbach-Ackley LP, Petersen JK, Wesseling P. Molecular pathology of tumors of the central nervous system. Ann Oncol. 2019;30(8):1265–1278. doi:10.1093/annonc/mdz164
   PubMed Web of Science ®Google Scholar
• Louis DN, Wesseling P, Paulus W, et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018;135(3):481–484. doi:10.1007/s00401-018-1808-0
   PubMed Web of Science ®Google Scholar
• Louis DN, Ellison DW, Brat DJ, et al. cIMPACT-NOW: a practical summary of diagnostic points from round 1 updates. Brain Pathol. 2019;29(4):469–472. doi:10.1111/bpa.12732
   PubMed Web of Science ®Google Scholar
• Castro LNG, Wesseling P. The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract. 2020;8(1):4–10. doi:10.1093/nop/npaa055
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Burger P, et al. International society of neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429–435. doi:10.1111/bpa.12171
   PubMed Web of Science ®Google Scholar
• Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135(4):639–642. doi:10.1007/s00401-018-1826-y
   PubMed Web of Science ®Google Scholar
• Gessi M, Capper D, Sahm F, et al. Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathol. 2016;132(4):635–637. doi:10.1007/s00401-016-1608-3
   PubMed Web of Science ®Google Scholar
• Hochart A, Escande F, Rocourt N, et al. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Ann Clin Transl Neurol. 2015;2(4):439–443. doi:10.1002/acn3.184
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Donson A, Foreman NK, Dorris K. H3 K27M mutation in gangliogliomas can be associated with poor prognosis. Brain Pathol. 2017;27(6):846–850. doi:10.1111/bpa.12455
   PubMed Web of Science ®Google Scholar
• Morita S, Nitta M, Muragaki Y, et al. Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. J Neurosurg. 2018;129(3):593–597. doi:10.3171/2017.4.JNS162443
   PubMed Web of Science ®Google Scholar
• Orillac C, Thomas C, Dastagirzada Y, et al. Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. Acta Neuropathol Commun. 2016;4(1):84. doi:10.1186/s40478-016-0361-0
   PubMedGoogle Scholar
• Pagès M, Beccaria K, Boddaert N, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103–111. doi:10.1111/bpa.12473
   PubMed Web of Science ®Google Scholar
• Pratt D, Natarajan SK, Banda A, et al. Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol. 2018;135(2):299–301. doi:10.1007/s00401-018-1805-3
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–612.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(5):805–810. doi:10.1007/s00401-018-1913-0
   PubMed Web of Science ®Google Scholar
• Korshunov A, Capper D, Reuss D, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 2016;131(1):137–146. doi:10.1007/s00401-015-1493-1
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–563. doi:10.1016/j.cell.2015.12.028
   PubMed Web of Science ®Google Scholar
• Stichel D, Ebrahimi A, Reuss D, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793–803. doi:10.1007/s00401-018-1905-0
   PubMed Web of Science ®Google Scholar
• Wijnenga MMJ, Dubbink HJ, French PJ, et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 2017;134(6):957–959. doi:10.1007/s00401-017-1781-z
   PubMed Web of Science ®Google Scholar
• Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020;22(4):515–523. doi:10.1093/neuonc/noz200
   PubMed Web of Science ®Google Scholar
• Ellison DW, Hawkins C, Jones DTW, et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol. 2019;137(4):683–687. doi:10.1007/s00401-019-01987-0
   PubMed Web of Science ®Google Scholar
• Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015;33(9):1015–1022. doi:10.1200/JCO.2014.58.3922
   PubMed Web of Science ®Google Scholar
• Qaddoumi I, Orisme W, Wen J, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016;131(6):833–845. doi:10.1007/s00401-016-1539-z
   PubMed Web of Science ®Google Scholar
• Smits A, Jakola AS. Clinical presentation, natural history, and prognosis of diffuse low-grade gliomas. Neurosurg Clin N Am. 2019;30(1):35–42. doi:10.1016/j.nec.2018.08.002
   PubMed Web of Science ®Google Scholar
• Brown NF, Carter T, Kitchen N, Mulholland P. Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol. 2017;6(4):291–296. doi:10.2217/cns-2017-0006
   PubMedGoogle Scholar
• Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–608. doi:10.1007/s00401-020-02127-9
   PubMed Web of Science ®Google Scholar
• Cimino PJ, Holland EC. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro Oncol. 2019;21(6):819–821. doi:10.1093/neuonc/noz052
   PubMed Web of Science ®Google Scholar
• Yoda RA, Marxen T, Longo L, et al. Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol. 2019;78(11):1002–1010. doi:10.1093/jnen/nlz082
   PubMed Web of Science ®Google Scholar
• Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585–596. doi:10.1007/s00401-015-1398-z
   PubMed Web of Science ®Google Scholar
• Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136(1):153–166. doi:10.1007/s00401-018-1849-4
   PubMed Web of Science ®Google Scholar
• Duregon E, Bertero L, Pittaro A, et al. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget. 2016;7(16):21190–21198. doi:10.18632/oncotarget.8498
   PubMedGoogle Scholar
• Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873. doi:10.1007/s00401-015-1438-8
   PubMed Web of Science ®Google Scholar
• Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66–77. doi:10.1093/neuonc/nox132
   PubMed Web of Science ®Google Scholar
• Korshunov A, Casalini B, Chavez L, et al. Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol. 2019;45(2):108–118. doi:10.1111/nan.12523
   PubMed Web of Science ®Google Scholar
• Reis GF, Pekmezci M, Hansen HM, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization grades II-III) astrocytomas. J Neuropathol Exp Neurol. 2015;74(5):442–452. doi:10.1097/NEN.0000000000000188
   PubMed Web of Science ®Google Scholar
• Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679–693. doi:10.1007/s00401-015-1409-0
   PubMed Web of Science ®Google Scholar
• Yang RR, Shi ZF, Zhang ZY, et al. IDH mutant lower grade (WHO grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol. 2020;30(3):541–553. doi:10.1111/bpa.12801
   PubMed Web of Science ®Google Scholar
• Appay R, Dehais C, Maurage CA, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519–1528. doi:10.1093/neuonc/noz126.000
   PubMed Web of Science ®Google Scholar
• Phillips JJ, Aranda D, Ellison DW, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013;23(5):565–573. doi:10.1111/bpa.12043
   PubMed Web of Science ®Google Scholar
• Richardson TE, Sathe AA, Kanchwala M, et al. Genetic and epigenetic features of rapidly progressing IDH-mutant astrocytomas. J Neuropathol Exp Neurol. 2018;77(7):542–548. doi:10.1093/jnen/nly026
   PubMed Web of Science ®Google Scholar
• Li KK, Shi ZF, Malta TM, et al. Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro Oncol Adv. 2019;1(1):vdz015. doi:10.1093/noajnl/vdz015
   PubMedGoogle Scholar
• Louis DN, Wesseling P, Aldape K, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844–856. doi:10.1111/bpa.12832
   PubMed Web of Science ®Google Scholar
• Haque F, Varlet P, Puntonet J, et al. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathol Commun. 2017;5:45. doi:10.1186/s40478-017-0449-1
   PubMed Web of Science ®Google Scholar
• Yoshimoto K, Hatae R, Sangatsuda Y, et al. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol. 2017;34(3):103–112. doi:10.1007/s10014-017-0287-7
   PubMed Web of Science ®Google Scholar
• Reinhardt A, Stichel D, Schrimpf D, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273–291. doi:10.1007/s00401-018-1837-8
   PubMed Web of Science ®Google Scholar
• Reinhardt A, Stichel D, Schrimpf D, et al. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol Commun. 2019;7(1):163. doi:10.1186/s40478-019-0801-8
   PubMed Web of Science ®Google Scholar
• Lehman NL, Usubalieva A, Lin T, et al. Genomic analysis demonstrates that histologically defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. Acta Neuropathol Commun. 2019;7(1):42. doi:10.1186/s40478-019-0689-3
   PubMedGoogle Scholar
• Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012;124(2):247–257.
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–743. doi:10.1016/j.ccell.2015.04.002
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017;133(1):5–12. doi:10.1007/s00401-016-1643-0
   PubMed Web of Science ®Google Scholar
• Pajtler KW, Wen J, Sill M, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol. 2018;136(2):211–226. doi:10.1007/s00401-018-1877-0
   PubMed Web of Science ®Google Scholar
• Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011;20(2):143–157. doi:10.1016/j.ccr.2011.07.007
   PubMed Web of Science ®Google Scholar
• Witt H, Gramatzki D, Hentschel B, et al. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro Oncol. 2018;20(12):1616–1624. doi:10.1093/neuonc/noy118
   PubMed Web of Science ®Google Scholar
• Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro Oncol. 2019;21(10):1319–1330. doi:10.1093/neuonc/noz069
   PubMed Web of Science ®Google Scholar
• Ellison DW, Aldape KD, Capper D, et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 2020;30(5):863–866. doi:10.1111/bpa.12866
   PubMed Web of Science ®Google Scholar
• Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011;10:7. doi:10.1186/1477-5751-10-7
   PubMedGoogle Scholar
• Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014;506(7489):445–450. doi:10.1038/nature13108
   PubMed Web of Science ®Google Scholar
• Panwalkar P, Clark J, Ramaswamy V, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 2017;134(5):705–714. doi:10.1007/s00401-017-1752-4
   PubMed Web of Science ®Google Scholar
• Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol. 2018;136(2):227–237. doi:10.1007/s00401-018-1888-x
   PubMed Web of Science ®Google Scholar
• Ghasemi DR, Sill M, Okonechnikov K, et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol. 2019;138(6):1075–1089. doi:10.1007/s00401-019-02056-2
   PubMed Web of Science ®Google Scholar
• Louis DN, Wesseling P, Brandner S, et al. Data sets for the reporting of tumors of the central nervous system: recommendations from the international collaboration on cancer reporting. Arch Pathol Lab Med. 2020;144(2):196–206. doi:10.5858/arpa.2018-0565-OA
   PubMed Web of Science ®Google Scholar
• Rushing EJ. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition. Memo. 2021;14(2):188–191. doi:10.1007/s12254-021-00680-x
   Google Scholar
• Cooney TM, Lubanszky E, Prasad R, Hawkins C, Mueller S. Diffuse midline glioma: review of epigenetics. J Neurooncol. 2020;150(1):27–34. doi:10.1007/s11060-020-03553-1
   PubMed Web of Science ®Google Scholar
• Deng MY, Sill M, Sturm D, et al. Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathol Appl Neurobiol. 2020;46(5):422–430. doi:10.1111/nan.12590
   PubMed Web of Science ®Google Scholar
• Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469–474. doi:10.1038/nature26000
   PubMed Web of Science ®Google Scholar
• Feldman AZ, Jennings LJ, Wadhwani NR, Brat DJ, Horbinski CM. The essentials of molecular testing in CNS tumors: what to order and how to integrate results. Curr Neurol Neurosci Rep. 2020;20(7):23. doi:10.1007/s11910-020-01041-7
   PubMed Web of Science ®Google Scholar
• Horbinski C, Ligon KL, Brastianos P, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019;21(12):1498–1508. doi:10.1093/neuonc/noz119
   PubMed Web of Science ®Google Scholar
• Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat Commun. 2018;9(1):4627. doi:10.1038/s41467-018-06715-y
   PubMedGoogle Scholar
• Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829–848. doi:10.1007/s00401-015-1432-1
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498.
   PubMed Web of Science ®Google Scholar
• Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):775–788. doi:10.1007/s00401-015-1410-7
   PubMed Web of Science ®Google Scholar
• Vaubel RA, Caron AA, Yamada S, et al. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol. 2018;28(2):172–182. doi:10.1111/bpa.12495
   PubMed Web of Science ®Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–484. doi:10.1007/s00401-012-0958-8
   PubMed Web of Science ®Google Scholar
• Kumar R, Liu APY, Northcott PA. Medulloblastoma genomics in the modern molecular era. Brain Pathol. 2020;30(3):679–690. doi:10.1111/bpa.12804
   PubMed Web of Science ®Google Scholar
• Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181–210. doi:10.1007/s00401-018-1879-y
   PubMed Web of Science ®Google Scholar
• Jaunmuktane Z, Capper D, Jones DTW, et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol Commun. 2019;7(1):24. doi:10.1186/s40478-019-0668-8
   PubMedGoogle Scholar
• Tanboon J, Williams EA, Louis DN. The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016;75(1):4–18. doi:10.1093/jnen/nlv009
   PubMed Web of Science ®Google Scholar
• Salem ME, Bodor JN, Puccini A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020;147(10):2948–2956. doi:10.1002/ijc.33115
   PubMed Web of Science ®Google Scholar
• McCord M, Steffens A, Javier R, Kam KL, McCortney K, Horbinski C. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol Commun. 2020;8(1):15. doi:10.1186/s40478-020-0892-2
   PubMed Web of Science ®Google Scholar
• Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22(12):1478–1490. doi:10.1634/theoncologist.2017-0242
   PubMed Web of Science ®Google Scholar
• Hodges TR, Ott M, Xiu J, et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017;19(8):1047–1057. doi:10.1093/neuonc/nox026
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Randomized Controlled Trial Nat Med. 2019;25(3):477–486. doi:10.1038/s41591-018-0337-7
   Google Scholar
• Gorsi HS, Malicki DM, Barsan V, et al. Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: a single institutional experience. J Pediatr Hematol Oncol. 2019;41(4):e235–e241. doi:10.1097/MPH.0000000000001339
   PubMed Web of Science ®Google Scholar
• Daniel P, Sabri S, Chaddad A, et al. Temozolomide Induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol. 2019;9:41. doi:10.3389/fonc.2019.00041
   PubMed Web of Science ®Google Scholar
• Hunter C, Smith R, Cahill DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66(8):3987–3991. doi:10.1158/0008-5472.CAN-06-0127
   PubMed Web of Science ®Google Scholar
• van Thuijl HF, Mazor T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607. doi:10.1007/s00401-015-1403-6
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implication. Neuro Oncol. 2021;23(8):1215–1217. doi:10.1093/neuonc/noab120
   PubMed Web of Science ®Google Scholar
• WHO Classification of Tumours. Central Nervous System Tumours. Edited by the WHO Classification of Tumours Editorial Board. 5th ed. International Agency for Research on Cancer (IARC); 2021.
   Google Scholar
• Baroni LV, Sundaresan L, Heled A, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 2021;23(8):1360–1370. doi:10.1093/neuonc/noab034
   PubMed Web of Science ®Google Scholar
• Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastoma revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020;20(1):42–56. doi:10.1038/s41568-019-0223-8
   PubMed Web of Science ®Google Scholar
• Fukuoka K, Mamatjan Y, Tatevossian R, et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro Oncol. 2020;22(10):1474–1483. doi:10.1093/neuonc/noaa077
   PubMed Web of Science ®Google Scholar